Literature DB >> 9425066

Differences in binding modes of enantiomers of 1-acetamido boronic acid based protease inhibitors: crystal structures of gamma-chymotrypsin and subtilisin Carlsberg complexes.

V S Stoll1, B T Eger, R C Hynes, V Martichonok, J B Jones, E F Pai.   

Abstract

In order to probe the structural basis of stereoselectivity in the serine protease family, a series of enantiomeric boronic acids RCH2CH(NHCOCH3)B(OH)2 has been synthesized and kinetically characterized as transition-state analog inhibitors using alpha-chymotrypsin and subtilisin Carlsberg as model systems. When the R-substituent in this series was changed from a p-chlorophenyl to a 1-naphthyl group, alpha-chymotrypsin, but not subtilisin, reversed its usual preference for l-enantiomers and bound more tightly to the D-enantiomer [Martichonok, V., & Jones, J. B. (1996) J. Am. Chem. Soc. 118, 950-958]. The structural factors responsible for the differences in stereoselectivity between the two enzymes have been explored by X-ray crystallographic examination of subtilisin Carlsberg and gamma-chymotrypsin complexes of the L- and D-enantiomers of p-chlorophenyl and 1-naphthyl boronic acid derivatives. In both enzymes, the L-isomers of the inhibitors, which are more closely related to the natural L-amino acid substrates, form tetrahedral adducts, covalently linking the central boron atom and Ogamma of the catalytic serine. The d-isomers, however, differ in the way they interact with subtilisin or gamma-chymotrypsin. With subtilisin, both the D-p-chlorophenyl and D-1-naphthyl inhibitor complexes form covalent Ser Ogamma-to-boron bonds, but with gamma-chymotrypsin, the same inhibitors lead to novel tetrahedral adducts covalently linking both Ser195 Ogamma and His57 Nepsilon2 covalently via the boron atom.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9425066     DOI: 10.1021/bi971166o

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Structural determinants of ligand imprinting: a molecular dynamics simulation study of subtilisin in aqueous and apolar solvents.

Authors:  Diana Lousa; António M Baptista; Cláudio M Soares
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

Review 2.  The versatility of boron in biological target engagement.

Authors:  Diego B Diaz; Andrei K Yudin
Journal:  Nat Chem       Date:  2017-07-25       Impact factor: 24.427

3.  Post-translational insertion of boron in proteins to probe and modulate function.

Authors:  Patrick G Isenegger; Brian Josephson; Tim A Mollner; Charles Buchanan; Lukas Lercher; Daniel Oehlrich; D Flemming Hansen; Shabaz Mohammed; Andrew J Baldwin; Véronique Gouverneur; Benjamin G Davis
Journal:  Nat Chem Biol       Date:  2021-11-01       Impact factor: 15.040

4.  Structural basis for dual-inhibition mechanism of a non-classical Kazal-type serine protease inhibitor from horseshoe crab in complex with subtilisin.

Authors:  Rajesh T Shenoy; Saravanan Thangamani; Adrian Velazquez-Campoy; Bow Ho; Jeak Ling Ding; J Sivaraman
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

5.  Probing contacts of inhibitor locked in transition states in the catalytic triad of DENV2 type serine protease and its mutants by 1H, 19F and 15 N NMR spectroscopy.

Authors:  Peter Agback; Esmeralda Woestenenk; Tatiana Agback
Journal:  BMC Mol Cell Biol       Date:  2020-05-25

6.  High-Throughput Crystallography Reveals Boron-Containing Inhibitors of a Penicillin-Binding Protein with Di- and Tricovalent Binding Modes.

Authors:  Hector Newman; Alen Krajnc; Dom Bellini; Charles J Eyermann; Grant A Boyle; Neil G Paterson; Katherine E McAuley; Robert Lesniak; Mukesh Gangar; Frank von Delft; Jürgen Brem; Kelly Chibale; Christopher J Schofield; Christopher G Dowson
Journal:  J Med Chem       Date:  2021-07-31       Impact factor: 8.039

7.  Reconstruction of ancestral protein sequences and its applications.

Authors:  Wei Cai; Jimin Pei; Nick V Grishin
Journal:  BMC Evol Biol       Date:  2004-09-17       Impact factor: 3.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.